Revolutionary technology pinpoints biopsies to detect prostate cancer

December 5, 2018, University College London
Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia

Medical software developed at UCL that overlays tumour information from MRI scans onto ultrasound images can help guide surgeons conducting biopsies and improve prostate cancer detection.

A team of engineers and medical researchers found that the technology enabled surgeons to pick up clinically relevant cancers that were missed when using current visual detection methods. The best approach would be to use both techniques in tandem, according to the findings published today in European Urology.

The software is deployed via a system called SmartTarget.

The advent of MRI-targeted biopsies, where MRI scans are used to inform surgeons where a tumour lies before they conduct a (tissue sample), has improved detection rates to close to 90% from 50% in the last five years.

Now, the SmartTarget system has further enhanced this technique by allowing a 3-D model of the prostate and to be created for each patient from their MRI scans using advanced image processing and machine learning algorithms.

During a biopsy, this model is fused with ultrasound images to highlight the area of concern, which otherwise does not appear in the ultrasound images, helping to guide the surgeon while conducting the procedure.

Until last year when MRI targeting was introduced, the established way to test for prostate cancer involved taking a biopsy from the prostate without knowing where in the prostate a tumour was likely to be, resulting in close to half of life-threatening cancers being missed.

"Prostate cancer detection has been improving at a very fast rate in recent years, and this technology pushes the science forward even further, enabling clinicians to pick up prostate cancer quickly so that patients can access the right treatment early enough," said co-senior author Professor Hashim Ahmed, who began the research in UCL Medicine before moving to Imperial College London.

For the present study, 129 people with suspected prostate cancer underwent two biopsies—one using the SmartTarget system, and one where surgeons could only visually review the MRI scans. Funded by the UK Department of Health and Social Care and Wellcome Health Innovation Challenge Fund, the study was conducted at UCLH.The two strategies combined detected 93 clinically significant prostate cancers, with each of them picking up 80 of these cancers; each missed 13 that the other method picked up.

The researchers say that surgeons' visual review of MRI scans should be used in tandem with SmartTarget as using this technique enables surgeons to learn to make subtle adjustments such as adapting to the movement of the patient and the prostate as the needle is inserted.

"We developed the SmartTarget system to equip surgeons with vital information about the size, shape and location of prostate tumours during a biopsy that is otherwise invisible on ," explained co-senior author Dr. Dean Barratt (UCL Medical Physics & Biomedical Engineering and UCL Centre for Medical Image Computing), who invented and led the development of the SmartTarget system.

"The software provides them with a clear target. As MRI-targeted biopsies require a very high degree of expertise and experience, we hope that the imagery displayed by SmartTarget will help to bring high accuracy diagnosis to a much wider range of patients and hospitals."

The researchers say the new methods could reduce the number of biopsies needed, and reduce the unnecessary surgeries caused by over diagnosis of less harmful cancers.

The SmartTarget software has been commercialised by SmartTarget Ltd, a company spun out by UCL's commercialisation company UCL Business PLC (UCLB), and the system is already in use by several hospitals in the UK and USA.

The inter-disciplinary study brought together engineers, urologists and radiologists, supported by the UCL Translational Research Office in project management and navigating the translational and regulatory pathway involved in taking the project from the lab bench to the operating room.

"There has been much discussion and speculation in the media recently on the degree to which computers and artificial intelligence will be integrated into clinical care. Studies such as this one are extremely important as they provide valuable evidence on the performance of a new technology in the clinical setting," said co-senior author Professor Mark Emberton (Dean, UCL Medical Sciences).

"With this study we now have hard data showing that SmartTarget is as good as a group of experts in targeting tumours in the , and have a glimpse of how clinicians and computers will be working together in the future for the good of the patient."

Explore further: Study shows targeted biopsy for prostate cancer more effective than traditional method

More information: European Urology (2018). DOI: 10.1016/j.eururo.2018.08.007

Related Stories

Study shows targeted biopsy for prostate cancer more effective than traditional method

May 15, 2018
Researchers at the University of Cincinnati (UC) have found that MRI fusion biopsy—coupling MRI and ultrasound to visualize suspicious lesions in the prostate gland and targeting the biopsy to that particular area—outperformed ...

One in four men with suspected prostate cancer could avoid unnecessary biopsy if given an MRI scan first

January 20, 2017
Giving men with suspected prostate cancer an MRI scan could improve diagnosis and save those who do not have aggressive cancers from having an unnecessary biopsy, according to a study published in The Lancet.

MRI scans for suspected prostate cancer could improve diagnosis

January 31, 2017
A researcher from Hull York Medical School (HYMS) has helped design and set up a study which has been hailed as the biggest leap in diagnosing prostate cancer in decades.

MRI risk model may cut biopsy use in suspected prostate cancer

February 26, 2018
(HealthDay)—A risk model including magnetic resonance imaging (MRI)-derived parameters may reduce the number of unnecessary biopsies among patients with suspected prostate cancer, according to a study published online Feb. ...

Researchers to investigate screening for prostate cancer using MRI—potentially replacing the PSA test

April 4, 2018
A new clinical study will test for the first time if MRI scans can be used for population screening to detect prostate cancer more accurately. The current prostate-specific antigen (PSA) test is considered too unreliable ...

Contrast-enhanced subharmonic imaging detects prostate cancers not identified by MRI

April 10, 2018
A test of contrast-enhanced subharmonic imaging (SHI) has shown promise in detecting prostate cancers that were not identified by MRI, according to a study to be presented at the ARRS 2018 Annual Meeting, set for April 22-27 ...

Recommended for you

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.